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Background: The influence of prolongation of hemodialysis (HD) period for erectile dysfunction (ED) has not been
well evaluated. We evaluated the effects of various factors including hemodialysis duration for ED in hemodialysis
patients.
Methods: One hundred seventy-eight HD patients including 50 patients who received HD more than 10 years were
enrolled in this study. The questionnaire of the International Index of Erectile Function (IIEF)-5 in Japanese language
was used for evaluation of ED status in this cohort. Various clinical factors of these patients were collected from review
of medical records, and the relationship between these factors and ED status was also evaluated.
Results: The prevalence of diabetes (p < 0.001), obesity (p = 0.011), and hyperuricemia (p = 0.010) were significantly
higher in patients with less than 10 years of HD (group 1) than those in patients with more than 10 years of
HD periods (group 2). The mean score of IIEF-5 in group 2 was almost similar with that in group 1 (p = 0.452).
Moderate to severe ED was also equivalent to that in group 1 (p = 0.988). More than 60 years old (p < 0.001)
and absence of hyperuricemia (p = 0.002) appeared to be significant risk factors for moderate to severe ED in
multivariate analysis.
Conclusions: Long periods of chronic hemodialysis therapy did not affect ED status, and absence of hyperuricemia
was the risk factor for moderate to severe ED in HD patients.
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Uremic condition is associated to various physical disor-
ders which impair patient’s quality of life. Erectile dys-
function (ED) is one of the common complications in
male hemodialysis (HD) patients. Its prevalence is esti-
mated to be approximately 20 to 80% in HD patients
[1–6]. Various factors such as vascular dysfunction,
neurogenic disturbance, adverse effect of medications,
depression, hormonal abnormalities, anemia, secondary
hyperparathyroidism, and zinc deficiency are related to
ED in HD patients [3, 5–8]. Some of those risk factors
for ED gradually progress with the extension of dialysis* Correspondence: hnishida331@yahoo.co.jp
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nificant risk factor of ED in HD patients is still contro-
versial, because of the relatively short period of dialysis
in those study cohorts and division of results. Moreover,
the difference of clinical risk factor for ED between
patients with short-term HD therapy and those with
long-term therapy still remains uncertain. Hence, we
evaluated the effects of various factors including HD
duration for ED in HD patients.Methods
From January to July 2011, male patients who were older
than 20 years old and received chronic HD therapy at 13
facilities in Yamagata prefecture were recruited to the
study. The study protocol was approved by the ethical
committee of the Yamagata University Faculty of Medicine.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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consent and voluntarily completed the questionnaire of
the International Index of Erectile Function (IIEF)-5 in
Japanese language that consisted of 5 questions eliciting
were enrolled in the study. An IIEF-5 score between 1 to
7 denotes a serious form of ED, 8 to 11 denotes moder-
ate, 12 to 16 denotes moderate to mild, 17 to 21 denotes
mild, and 22 to 25 denotes no ED. The information
about past history of smoking, alcohol consumption,
presence of sexual partner, and past history of treatment
for ED were also obtained by the questionnaire.
Terms of patient’s background including age, duration
of HD therapy, primary disease, presence of comorbidi-
ties, and current medications were collected from review
of medical records. Attending physician in each facility
evaluated the presence of each comorbidity based on pa-
tient’s clinical status, laboratory data, and medication
profile. Patients were divided into two groups: patients
with less than 10 years of HD periods were in group 1,
and those with more than 10 years were in group 2.
Various parameters including patient’s backgrounds
and clinical features were compared between two
groups. In order to evaluate differences between groups,
Chi-square, Student’s t test, Mann–Whitney U test, and
Fisher’s exact test were used as appropriate. Multivariate
association between these factors and ED were measured
with odds ratio (OR). Multivariable logistic regression
analysis was used to examine the associations between
predictor variables and ED. Significance of the individual
regression estimates was tested by Wald statistics. The sig-
nificance level was set at 0.05 for all tests. All statistical
analyses were performed with EZR (Saitama Medical
Center, Jichi Medical University, Saitama, Japan), which is
a graphical user interface for R (The R Foundation for
Statistical Computing, Vienna, Austria) [9]. More pre-
cisely, it is a modified version of R commander designed
to add statistical functions frequently used in biostatistics.
Results
Two hundred of chronic HD male patients in 13 institu-
tions participated in this study. Eight patients were ex-
cluded because they did not completed the EF domain
from IIEF-5 in questionnaire, and 14 patients were also
excluded because of their past history of medical treat-
ment for ED. Thus, the sample was composed of 178
patients.
Patient’s background was shown in Table 1. The number
of patients whose duration of chronic HD was shorter
than 10 years (group 1) was 128, and that of the others
who received chronic HD more than 10 years (group 2)
was 50. Mean duration of HD was 4.5 ± 2.5 years in group
1 and 17.3 ± 5.4 years in group 2 (p < 0.001). Body mass
index (BMI) was significantly lower in group 2 (p = 0.011).
The most frequent primary disease of end-stage renaldisease was diabetes mellitus (DM) nephropathy in group
1, while that in group 2 was chronic glomerular nephritis
(CGN) (p = 0.016). The prevalence of DM was also higher
in group 1 (p < 0.001). Group 1 had a high frequency of
hyperuricemia (p = 0.010) and a lower frequency of liver
dysfunction (p = 0.031). The prevalence of other comor-
bidities was not significantly different between the 2
groups. Chronic kidney disease mineral and bone disorder
(CKD-MBD) status including serum calcium (Ca), phos-
phate (P), and intact parathyroid hormone (iPTH) levels
was also compared between 104 of 128 patients and 41 of
50 patients whose data of these parameters could be col-
lected from medical records. Serum Ca (9.0 ± 0.8 mg/dL
and 9.1 ± 0.8 mg/dL; p = 0.366), P (5.7 ± 1.7 mg/dL and
5.4 ± 1.6 mg/dL; p = 0.477), and iPTH (154.1 ± 124.5 pg/mL
and 147.3 ± 125.7 pg/mL; p = 0.645) were not significantly
different between the 2 groups.
IIEF-5 scores and grade of ED assessed by IIEF-5 in
each group were shown in Table 2. The mean score of
IIEF-5 in group 2 was almost similar with that in group
1 (p = 0.452). The rate of each ED grade assessed by
IIEF-5 score in group 2 was also comparable to that of
group 1 (p = 0.959). Moderate to severe ED on the basis
of IIEF-5 score in group 2 was 66%, which was almost
equivalent to 68% in group 1 (p = 0.849).
On univariate analysis, associated risk factors for mod-
erate to severe ED on the basis of IIEF-5 score were age
older than 60 years (p < 0.001) and absence of hyperuri-
cemia (p = 0.008) (Table 3). HD duration more than
10 years was demonstrated not to be the significant risk
factor for moderate to severe ED (p = 0.779). We also
evaluated the relationship between ED and these risk fac-
tors in multivariate analysis. While HD duration also did
not have significant correlation with moderate to severe
ED in this analysis, age more than 60 years old (p < 0.001)
and absence of hyperuricemia (p = 0.005) appeared to be
important correlate of moderate to severe ED.
Discussion
As a result of improvement in HD therapy and small
number of kidney transplantation due to extreme short-
age of kidney donation in Japan, the number of both
end-stage renal disease (ESRD) patients with long-term
chronic HD therapy and patients who receive short
period of chronic HD but have various comorbidities are
gradually increasing [10]. Several cross-sectional studies
revealed that ED is a very common disease in ESRD pa-
tients; however, the influence of long-term chronic HD
for ED was not well evaluated. In this study, the fre-
quency of ED was almost equivalent between short-term
HD patients and long-term patients, and hyperurice-
mia was demonstrated to be an independent risk
factor in not only all patients but also long-term
hemodialysis patients.
Table 1 Patient demographics





n = 178 (Group 1; n = 128) (Group 2; n = 50)
Age mean ± SD (years) 59.2 ± 10.7 60.0 ± 10.5 57.4 ± 11.0 0.19
Duration of dialysis mean ± SD (years) 8.1 ± 6.8 4.5 ± 2.5 17.3 ± 5.4 <0.001
Body mass index mean ± SD (kg/m/m) 23.5 ± 8.4 24.3 ± 8.7 21.2 ± 7.1 0.01
Primary renal diseases 0.02
Diabetes mellitus n (%) 54 (30) 49 (38) 5 (10)
Chronic glomerular nephritis n (%) 64 (36) 34 (27) 30 (60)
Hypertensive nephrosclerosis n (%) 13 (7) 12 (9) 1 (2)
Others n (%) 47 (26) 33 (26) 14 (28)
Comorbidities
Hypertension n (%) 156 (88) 115 (90) 41 (82) 0.19
Diabetes mellitus n (%) 48 (27) 45 (35) 3 (6) <0.001
Hyperlipidemia n (%) 25 (14) 20 (16) 5 (10) 0.47
Hyperuricemia n (%) 42 (25) 37 (29) 5 (10) 0.010
Cardiovascular disease n (%) 36 (20) 30 (23) 6 (12) 0.100
Cerebrovascular disease n (%) 13 (7) 8 (6) 5 (10) 0.52
Liver dysfunction n (%) 10 (6) 4 (3) 6 (12) 0.03
Depression n (%) 2 (1) 2 (2) 0 (0) 1
Smoking 0.699
Former smoker n (%) 90 (51) 62 (48) 28 (56)
Current smoker n (%) 41 (23) 31 (24) 10 (20)
Alcohol consumption 0.39
Social drinker n (%) 70 (39) 47 (37) 23 (46)
Daily drinker n (%) 20 (11) 14 (11) 6 (12)
Presence of sexual partner n (%) 131 (74) 100 (78) 31 (62) 0.08
SD standard deviation, HD hemodialysis
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hyperparathyroidism and arteriosclerosis due to pro-
longed chronic hemodialysis are well-known to be get-
ting worsen progressively [11]. ED status in ESRD
patients with long-term chronic HD was predicted to be
progressed; however, long-term chronic HD did not ap-
pear to deteriorate ED status under adjustment ofTable 2 IIEF-5 score and ED status in HD patients
All patients HD du
n = 178 (Group
IIEF-5 score mean ± SD 8.9 ± 7.1 8.8 ± 7
Grade of ED (IIEF-5 scores)
No ED (22–25) n (%) 17 (10) 13 (10
Mild (17–21) n (%) 16 (9) 11 (9)
Mild to moderate (12–16) n (%) 23 (13) 16 (13
Moderate (8–11) n (%) 29 (16) 20 (16
Severe (1–7) n (%) 91 (51) 67 (52
IIEF-5 International Index of Erectile Function-5, ED erectile dysfunction, SD standardvarious factors. This is a cross-sectional study based on
questionnaire and we could not include various clinical
factors such as high-intact parathyroid hormone level,
zinc deficiency, evaluation of malnutrition status, and
degree of arteriosclerosis. Among these parameters, de-
gree of arteriosclerosis might not be advanced in ESRD
patients with long-term HD as strong as we suspectedration <10 years patients HD duration ≥10 years patients p values
1; n = 128) (Group 2; n = 50)








Table 3 Odds ratio of ED in HD patients for variables included in univariate analysis and multivariate analysis
Univariate analysis Multivariate analysis
Odds ratio 95% CI p value Odds ratio 95% CI p value
Age ≥60 years 3.110 1.680–5.740 <0.001 3.610 1.890–6.880 <0.001
HD duration ≥10 years 0.910 0.473–1.750 0.779
BMI ≥25 0.736 0.394–1.38 0.337
Hypertension 0.761 0.361–1.600 0.472
Diabetes mellitus 1.830 0.928–3.600 0.081
Hyperlipidemia 1.220 0.523–2.870 0.642
Hyperuricemia 0.372 0.180–0.768 0.008 0.303 0.139–0.656 0.002
Cardiovascular disease 1.400 0.668–2.930 0.373
Cerebrovascular disease 1.540 0.484–4.910 0.463
Liver dysfunction 0.606 0.165–2.230 0.451
Smoking 0.803 0.563–1.140 0.225
Alcohol consumption 0.714 0.460–1.110 0.132
Presence of sexual partner 0.504 0.250–1.010 0.055
Ca >10 mg/dL 0.437 0.125–1.520 0.193
P >6 mg/dL 0.969 0.475–1.980 0.930
iPTH >250 pg/mL 1.450 0.623–3.400 0.387
HD hemodialysis, BMI body mass index, ED erectile dysfunction, Ca calcium, P phosphate, iPTH intact parathyroid hormone
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with long-term HD was not larger than those in patient
with short-term HD even though they had long duration
of chronic kidney disease. Prospective cohort study
which assess progression of ED status according to pro-
longation of hemodialysis period and include various
clinical factors which are mentioned above might be
more eligible to assess whether long-term HD affect ED
severity or not.
Hyperuricemia was well-known as a risk factor for vari-
ous vascular complications such as stroke, coronary dis-
ease, heart failure, and chronic kidney disease [12–15]. ED
is closely associated with endothelial dysfunction and
CVD, and the relationship between coronary artery dis-
ease and high uric acid level was reported [16]. On the
other hand, inverse correlation between uric acid levels
and all causes and CVD mortality in HD population was
reported in contrast to the association of hyperuricemia
and CVD risk in general population [17]. While the possi-
bilities of surrogate for a better nutritional status and anti-
oxidative properties of uric acid were pointed out, the
potential mechanisms of this association in HD patients
still remain uncertain[17, 18]. This cardioprotective mech-
anism of hyperuricemia in HD population might contrib-
ute to lower frequency of ED.
There are various considerations in this study that
limit our findings. First, this is a relatively small sample
size cross-sectional study. Second, we enrolled only pa-
tients who accepted our proposal and filled out the
questionnaire so that we could not reflect informationon patients who refused to participate or excluded from
the study cohort. Third, IIEF-5 based on self-reporting
was the only tool to evaluate ED in this study, and no
other physical and diagnostic tests which evaluated not
only ED status but also pathogenesis factors. Last, we
could not assess influence of variables which have been
reported to be linked to ED, such as autonomic neur-
opathy, residual renal function, hormonal status, anemia,
secondary hyperparathyroidism, zinc deficiency, and so
on. Prospective large cohort study including various
clinical factors as mentioned above will be needed to ad-
dress this subject.
Conclusions
In conclusion, longer periods of chronic HD therapy did
not affect ED status, and there is reverse correlation be-
tween hyperuricemia and ED status of ESRD patients
with either short or long periods of chronic HD. Further
evaluation for the reason why hyperuricemia improve
ED status in HD patients is needed.
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